

China Biologic clocks 19% growth in 2014 turnover

05 March 2015 | Company results | By BioSpectrum Bureau

China Biologic clocks 19% growth in 2014 turnover



Singapore: China Biologic Products clocked \$243.3 million in 2014, marking a jump of 19.6 percent from 2013 that scaled to \$203.4 million.

Mr David (Xiaoying) Gao, chairman and chief executive officer, China Biologic, commented, "We are very pleased to finish 2014 with strong top line and bottom line growth, significant operational developments, as well as an improved shareholder structure. Our healthy financial growth was supported by strong market demand, stable product pricing, increased production capacity after the renewal of GMP certification at our Guizhou facility, stringent cost control measures, the optimization of our product portfolio mix and the successful implementation of our sales strategy in tier-one cities."

"In 2014, we experienced a double-digit increase in our plasma collection volume for the third consecutive year, primarily through organic growth at our existing collection centers. We are pleased with our many accomplishments throughout the year. Highlights include receiving the approval to build two new plasma collection centers in Hebei Province, receiving production approval for human PCC products, increasing IVIG sales in tier-one cities, and expanding our production capacity of, and implementing an in-house sales strategy for, placenta polypeptide products. These combined efforts contributed to our considerable top line growth and improved operational efficiency in the fourth quarter and will contribute to our overall growth in the years to come."